HCT/P: FDA’s Newest Regulatory Battleground
February 25, 2015

Axinn Counsel Stacie Ropka presented at a webinar entitled, “HCT/P: FDA’s Newest Regulatory Battleground.” She provided an exclusive analysis of the FDA oversight of HCT/Ps with a focus on what the draft guidelines mean to manufacturers.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.